AstraZeneca: Saxa-dapa might be approved this week

Saxa-dapa is a key asset for AZN’s diabetes franchise which could be approved in the US as early as this week. In April 2014, AZN said it could be a USD3bn opportunity. We are not yet at this level but an approval would be a clear incentive for AZN to support its diabetes franchise further.

For more information, please contact marketing@bryangarnier.com